Patents Assigned to Ignyta, Inc.
  • METHODS FOR TREATING NEUROBLASTOMA
    Publication number: 20180333412
    Abstract: Methods of treating neuroblastoma associated with a deregulated protein kinase activity are disclosed. The treatment may include administration of substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts therefor, as degined in the specification.
    Type: Application
    Filed: July 31, 2018
    Publication date: November 22, 2018
    Applicants: IGNYTA, INC., Nerviano Medical Sciences S.r.I.
    Inventors: Jonathan LIM, Elena ARDINI, Maria MENICHINCHERI
  • Combinations for the treatment of neuroblastoma
    Patent number: 10085979
    Abstract: Disclosed are methods of treating neuroblastoma in a cancer patient by administration of a Trk inhibitor in combination with one more chemotherapeutic agents. Also disclosed are pharmaceutical compositions comprising a Trk inhibitor and one or more chemotherapeutic agents.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: October 2, 2018
    Assignee: IGNYTA, INC.
    Inventors: Zachary Dolph Hornby, Gang Li, David Wesley Anderson, Garrett M. Brodeur, Radhika Iyer
  • TOPICAL FORMULATIONS
    Publication number: 20180256570
    Abstract: Described herein are pharmaceutical formulations comprising 4-fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical formulations are suitable for topical use, and methods of using such formulations in the treatment of subjects having cancer.
    Type: Application
    Filed: November 28, 2016
    Publication date: September 13, 2018
    Applicant: IGNYTA, INC.
    Inventors: Jeffrey Alan PETERSON, Stephanie Ann SWEETANA
  • Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents
    Patent number: 10028956
    Abstract: This application describes the use of the compound (I) or a salt thereof, either alone or in combination with other therapeutically active agents, for the treatment of particular cancers, including any solid or hematological cancer in which AXL or c-Met is over-expressed.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: July 24, 2018
    Assignee: IGNYTA, INC.
    Inventors: Thelma S. Angeles, Mark A. Ator, Mangeng M. Cheng, Bruce Dorsey, Robert L. Hudkins, Bruce A. Ruggeri
  • Uracil derivatives as AXL and c-MET kinase inhibitors
    Patent number: 10017496
    Abstract: The present invention provides compounds of Formula I or pharmaceutically acceptable salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, methods of treatment and uses thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 10, 2018
    Assignee: IGNYTA, INC.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH RTK MUTANT CELLS
    Publication number: 20180177792
    Abstract: Disclosed herein are compositions and methods for treating cancer patients who have been previously treated with one or more chemotherapeutic agents and have developed at least partial resistance to such chemotherapeutic agents. Also disclosed are methods for selecting compounds suitable for treatment of cancer in a patient who has become resistant to an inhibitor of a receptor tyrosine kinase (RTK).
    Type: Application
    Filed: May 25, 2016
    Publication date: June 28, 2018
    Applicant: IGNYTA, INC.
    Inventor: Ge WEI
  • Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor
    Patent number: 9987281
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 5, 2018
    Assignee: IGNYTA, INC.
    Inventors: Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
  • BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME
    Publication number: 20180147186
    Abstract: The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.
    Type: Application
    Filed: January 24, 2018
    Publication date: May 31, 2018
    Applicant: IGNYTA, INC.
    Inventors: Roger P. BAKALE, Peter D. BROWN, Jian CHEN, Anthony S. DRAGER, Rachel Y. LABELL, Robert E. MCKEAN, Piyush R. PATEL, Renee C. ROEMMELE
  • PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE
    Publication number: 20180148447
    Abstract: The invention is directed to pyrazolo[1,5-a]pyridine derivatives and their use as AXL and c-MET kinase inhibitors.
    Type: Application
    Filed: January 24, 2018
    Publication date: May 31, 2018
    Applicant: IGNYTA, INC.
    Inventors: Robert L. HUDKINS, Allison L. Zulli
  • Bendamustine derivatives and methods of using same
    Patent number: 9913827
    Abstract: The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: March 13, 2018
    Assignee: IGNYTA, INC.
    Inventors: Roger P. Bakale, Peter D. Brown, Jian Chen, Anthony S. Drager, Rachel Y. LaBell, Robert E. McKean, Piyush R. Patel, Renee C. Roemmele
  • Pyrazolo[1,5-a]pyridine derivatives and methods of their use
    Patent number: 9914731
    Abstract: The invention is directed to pyrazolo[1,5-a]pyridine derivatives and their use as AXL and c-MET kinase inhibitors.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 13, 2018
    Assignee: IGNYTA, INC.
    Inventors: Robert L Hudkins, Allison L Zulli
  • MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER
    Publication number: 20170356918
    Abstract: The present disclosure generally relates to methods and compositions for identifying and/or treating cancer patients harboring one or more molecular alterations in clinically important biomarkers, preferably in multiplexed assays, such that multiple biomarkers can be assayed simultaneously. In one embodiment, the disclosure relates to methods for rapid screening large populations of biological samples by using a high-throughput multiplexed assay to assess relative prevalence of multiple indications, optionally followed by a second analytical assay with higher sensitivity and specificity.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 14, 2017
    Applicant: IGNYTA, INC.
    Inventors: Jason Hans CHRISTIANSEN, Danielle Anthea MURPHY, Aaron Scott BOOMER, Jennifer Lyn LAMOUREUX
  • URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS
    Publication number: 20170320853
    Abstract: The present invention provides compounds of Formula I or pharmaceutically acceptable salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c,Y, R3, X, E and G are as defined herein, methods of treatment and uses thereof.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 9, 2017
    Applicant: IGNYTA, INC.
    Inventors: Reddeppa Reddy DANDU, Robert L. HUDKINS, Kurt A. JOSEF, Catherine P. PROUTY, Rabindranath TRIPATHY
  • SOLID STATE FORMS OF A QUINAZOLINE DERIVATIVE AND ITS USE AS A BRAF INHIBITOR
    Publication number: 20170290833
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 12, 2017
    Applicant: IGNYTA, INC.
    Inventors: Stephen J. BIERLMAIER, Ralph C. HALTIWANGER, Martin J. JACOBS
  • Uracil derivatives as AXL and c-MET kinase inhibitors
    Patent number: 9745283
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 29, 2017
    Assignee: IGNYTA, INC.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor
    Patent number: 9718810
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 1, 2017
    Assignee: IGNYTA, INC.
    Inventors: Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
  • BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME
    Publication number: 20170182008
    Abstract: The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.
    Type: Application
    Filed: March 10, 2017
    Publication date: June 29, 2017
    Applicant: IGNYTA, INC.
    Inventors: Roger P. Bakale, Peter D. Brown, Jian Chen, Anthony S. Drager, Rachel Y. LaBell, Robert E. McKean, Piyush R. Patel, Renee C. Roemmele
  • Bendamustine derivatives and methods of using same
    Patent number: 9630926
    Abstract: The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: April 25, 2017
    Assignee: IGNYTA, INC.
    Inventors: Roger P. Bakale, Peter D. Brown, Jian Chen, Anthony S. Drager, Rachel Y. LaBell, Robert E. McKean, Piyush R. Patel, Renee C. Roemmele
  • Uracil derivatives as AXL and c-MET kinase inhibitors
    Patent number: 9522902
    Abstract: The present application provides compounds of Formula I or salt forms thereof, wherein Ra, Rb, Rc, Rd, D, W, R1a, R1b, R1c, Y, R3, X, E and G are as defined herein, compositions, methods of treatment and uses thereof.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: December 20, 2016
    Assignee: Ignyta, Inc.
    Inventors: Reddeppa Reddy Dandu, Robert L. Hudkins, Kurt A. Josef, Catherine P. Prouty, Rabindranath Tripathy
  • BENDAMUSTINE DERIVATIVES AND METHODS OF USING SAME
    Publication number: 20160289198
    Abstract: The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.
    Type: Application
    Filed: June 16, 2016
    Publication date: October 6, 2016
    Applicant: Ignyta, Inc.
    Inventors: Roger P. BAKALE, Peter D. BROWN, Jian CHEN, Anthony S. DRAGER, Rachel Y. LABELL, Robert E. MCKEAN, Piyush R. PATEL, Renee C. ROEMMELE